19 April 2024
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Share Options
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of unapproved share options over ordinary shares of 1 penny each to directors as follows.
Lisa Baderoon 3,000,000 share options (exercise price: 2.24p)
Laurence Reilly 2,000,000 share options (exercise price: 2.24p)
Share Option Period: All Share Options are valid for 10 years from the date of issue and will vest three years from the date of issue.
ENDS
|
For further information please contact:
|
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
For additional information about ImmuPharma please visit www.immupharma.co.uk
ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.
|
|
|
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Lisa Baderoon |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Director |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
ImmuPharma PLC |
|
|
b) |
LEI |
213800VZKGHXC7VUS895 |
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010 |
|
|
b) |
Nature of the transaction |
Grant of share options over new Ordinary Shares |
|
|
c)
|
Price(s) and volume(s)
|
Exercise Price |
Volume |
|
2.24 pence |
3,000,000 |
||
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|
|
e) |
Date of the transaction |
18 April 2024 |
|
|
f) |
Place of the transaction |
n/a |
|
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||
|
a) |
Name |
Laurence Reilly |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Senior Non-Executive Director |
|
|
b) |
Initial notification /Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
ImmuPharma PLC |
|
|
b) |
LEI |
213800VZKGHXC7VUS895 |
|
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a)
|
Description of the financial instrument, type of instrument
Identification code
|
Ordinary Shares of 1p each
ISIN: GB0033711010 |
|
|
b) |
Nature of the transaction |
Grant of share options over new Ordinary Shares |
|
|
c)
|
Price(s) and volume(s)
|
Exercise Price |
Volume |
|
2.24 pence |
2,000,000 |
||
|
|
|
|
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A |
|
|
e) |
Date of the transaction |
18 April 2024 |
|
|
f) |
Place of the transaction |
n/a |
|
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
